See more : Synergia Energy Ltd (SYN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Day One Biopharmaceuticals, Inc. (DAWN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Day One Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ecovyst Inc. (ECVT) Income Statement Analysis – Financial Results
- Phoenix New Media Limited (FENG) Income Statement Analysis – Financial Results
- Korea Airport Service Co.,Ltd. (005430.KS) Income Statement Analysis – Financial Results
- Heijmans N.V. (0M6I.L) Income Statement Analysis – Financial Results
- Marquee Raine Acquisition Corp. (MRAC) Income Statement Analysis – Financial Results
Day One Biopharmaceuticals, Inc. (DAWN)
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 383.00K | 531.00K | 199.00K | 155.00K | 0.00 |
| Gross Profit | -383.00K | -531.00K | -199.00K | -155.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 130.52M | 85.62M | 43.58M | 9.10M | 13.90M |
| General & Administrative | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.54M | 61.29M | 29.16M | 4.68M | 1.01M |
| Other Expenses | 1.00 | -18.00K | -15.00K | -31.00K | -2.00K |
| Operating Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Cost & Expenses | 206.06M | 146.91M | 72.74M | 13.78M | 14.91M |
| Interest Income | 17.19M | 4.75M | 4.00K | 30.00 | 2.08K |
| Interest Expense | 0.00 | 4.75M | 4.00K | 30.00K | 2.08M |
| Depreciation & Amortization | 383.00K | 531.00K | 199.00K | 155.00K | 14.91M |
| EBITDA | -206.06M | -141.65M | -72.56M | -43.66M | -2.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -206.06M | -146.91M | -72.74M | -13.78M | -14.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.15M | 4.73M | -11.00K | -30.06M | -2.08M |
| Income Before Tax | -188.92M | -142.18M | -72.75M | -43.84M | -16.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.01M | -2.31M | -3.34M | -2.27M |
| Net Income | -188.92M | -132.18M | -70.44M | -40.51M | -14.71M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| EPS Diluted | -2.37 | -2.02 | -1.14 | -0.65 | -0.24 |
| Weighted Avg Shares Out | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
| Weighted Avg Shares Out (Dil) | 79.77M | 65.47M | 61.95M | 61.93M | 61.93M |
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago.
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced...
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF...
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it...
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024
Source: https://incomestatements.info
Category: Stock Reports